Company Profile
Liquidia Corporation Stock Price, News & Catalysts
- Ticker:
- LQDA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
77.70 USD (+4.38%)
Close
Last updated: August 17, 2026
4.9B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, LQDA closed up 4.38% at $77.70. No new same-company headline was identified in the current news window.
Company overview
Pulmonary Hypertension Company
Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines.
YUTREPIA
YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved in the United States for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
PRINT Technology
Liquidia's PRINT manufacturing platform produces particles with controlled size, shape, and composition. The company uses this capability to create inhaled formulations intended to simplify administration and support dose flexibility.
L606
L606 is a sustained-release inhaled formulation of treprostinil delivered twice daily with a next-generation nebulizer. The pivotal Re-Spire study is evaluating the program in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Clinical Expansion Strategy
Liquidia is conducting multiple studies across YUTREPIA and L606 to generate evidence in established indications and explore additional uses for inhaled treprostinil.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Liquidia Corporation (LQDA)?
Liquidia Corporation (LQDA) most recently closed at 77.70 USD, a +4.38% move versus the previous session.
What is the market cap of Liquidia Corporation (LQDA)?
Liquidia Corporation currently has a market capitalization of 4.9B USD on BioPharmSignal.
What does Liquidia Corporation do?
Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved in the United States...
On which exchange is LQDA stock listed?
Liquidia Corporation (LQDA) is associated with NASDAQ, United States, Biopharma.
What is Pulmonary?
Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension.
Which conditions is Liquidia Corporation targeting with Pulmonary?
Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved in the United States...
What is Hypertension?
Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension.
What is Liquidia?
Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension.